Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
11/2003
11/04/2003US6642008 Assays and therapies for latent viral infection
11/04/2003CA2257322C Thiazole derivatives
10/2003
10/30/2003WO2003089596A2 Novel prostate tumor-specific promoter
10/30/2003WO2003089583A2 Tissue specific genes and gene clusters
10/30/2003WO2003089569A2 Use of il-19, il-22 and il-24 to treat hematopoietic disorders
10/30/2003WO2003089439A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and method for the production thereof
10/30/2003WO2003089438A1 Labeled oxazinocarbazoles as diagnostic agents
10/30/2003WO2003089434A2 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF
10/30/2003WO2003089430A1 Thioxanthine derivatives as myeloperoxidase inhibitors
10/30/2003WO2003089428A1 Tricyclic thrombin receptor antagonists
10/30/2003WO2003089410A1 Phenylalanine derivative
10/30/2003WO2003089404A1 Naphthalene amides as potassium channel openers
10/30/2003WO2003088984A1 Compositions and methods for augmenting kidney function
10/30/2003WO2003088972A1 Novel compounds
10/30/2003WO2003088956A1 Method for treating ileus with an alpha -ketoalkanoic acid or - ester or - amide
10/30/2003WO2003088955A1 Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt
10/30/2003WO2003088900A2 Solid forms of salts with tyrosine kinase activity
10/30/2003WO2003088748A1 Use of heme oxygenase-1 and products of heme degradation
10/30/2003WO2003073841A3 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
10/30/2003WO2003063796A3 Heterocyclic arylsulfonamidobenzylic compounds
10/30/2003WO2003051277A3 Novel compounds
10/30/2003WO2003051274A3 Benzodiazepine derivatives, preparation thereof and use thereof
10/30/2003WO2003037246A3 Compositions and methods for prostate and kidney health and disorders, an herbal preparation
10/30/2003WO2003028527A3 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
10/30/2003WO2003025199A3 Mid 4460, a human tyrosine phosphatase family member and uses therefor
10/30/2003WO2003018836A3 Model of autoimmune disease and methods for identifying agents against autoimmune disease
10/30/2003WO2003016549A3 Nucleic-acid associated proteins
10/30/2003WO2002103042A3 Method and nucleic acids for the differentiation of prostate tumors
10/30/2003WO2002097030A3 Peptides derived from neural thread proteins and their medical use
10/30/2003WO2002085458A3 Use of nk-1 receptor antagonists against benign prostatic hyperplasia
10/30/2003WO2002034783A3 Transmembrane proteins
10/30/2003WO2002032447A3 Cell damage inhibitor
10/30/2003WO2002018583A9 Modified polypeptides stabilized in a desired conformation and methods for producing same
10/30/2003US20030204206 Electrically responsive promoter system
10/30/2003US20030204086 Novel heterocyclic amide derivatives
10/30/2003US20030204052 Comprises polypeptide for treatment and prevention of autoimmune, cancer, inflammatory, nervous system, cardiomyopathy and atherosclerotic disorders
10/30/2003US20030203973 Administering triethylenetetramine to lower copper value of myocardium; for treatment of diabetes
10/30/2003US20030203966 Such as N-(3,5-dimethyl-4-((nitromethyl)sulphonyl) phenyl)benzenesulphonamide for treatment/prevention of peripheral and autonomous neurolgical diabetic complications, renal and ocular disorders (cataracts, retinopathy)
10/30/2003US20030203962 Purified plant proanthocyanidin extract, capable of inhibiting agglutination of P-type Escherichia coli and not capable of inhibiting agglutination of type 1 Escherichia coli; proanthocyanidin having 4-12 epicatechin flavanoid units
10/30/2003US20030203961 A taxane joined by a hydrolyzable bond to one or more oligomers that containing a polyethylene glycol group and a tert-amide group
10/30/2003US20030203957 Selected fused pyrrolocarbazoles
10/30/2003US20030203927 Thrombin receptor antagonists
10/30/2003US20030203915 Compounds that are nitrosated and/or nitrosylated through one or more sites such as oxygen (hydroxyl condensation), sulfur (sulfhydryl condensation) and/or nitrogen
10/30/2003US20030203913 Beta3 adrenergic receptor agonists and uses thereof
10/30/2003US20030203899 Drugs for incontinence
10/30/2003US20030203896 Novel guanidino derivatives as inhibitors of cell adhesion
10/30/2003US20030203893 Benzimidazole derivatives, preparation and therapeutic use thereof
10/30/2003US20030203057 A mixture of isoflavones or isoflavone glycosides, pungent, bitter and sour substances and/or scymnol and scymnol esters; secretion of biogenic monoamines; antidepressants; seasonal affective disorder; Alzheimer's disease and much more!
10/30/2003US20030203055 Administering a selective norepinephrine norepinephrine-serotonin reuptake inhibitor, e.g., milnacipran, that is not a tricylcic antidepressant; gastrointestinal and urogenital disorders; analgesics
10/30/2003US20030202939 Forming oxygen free radicals; destroying tumor, cancer
10/30/2003EP1496982A2 Solid forms of salts with tyrosine kinase activity
10/30/2003CA2752132A1 Thioxanthine derivatives as myeloperoxidase inhibitors
10/30/2003CA2482991A1 Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
10/30/2003CA2482907A1 Tissue specific genes and gene clusters
10/30/2003CA2482260A1 Use of heme oxygenase-1 and products of heme degradation
10/30/2003CA2482022A1 Novel compounds
10/30/2003CA2481753A1 Method for treating ileus with an alpha -ketoalkanoic acid or - ester or - amide
10/30/2003CA2481749A1 Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt
10/30/2003CA2480325A1 Solid forms of salts with tyrosine kinase activity
10/30/2003CA2478991A1 Compositions and methods for augmenting kidney function
10/30/2003CA2466229A1 Use of il-19, il-22 and il-24 to treat hematopoietic disorders
10/29/2003WO2002092081A1 Method of treatment
10/29/2003EP1357181A1 Novel atopic dermatitis-associated gene and proteins
10/29/2003EP1357131A2 Treatment of lupus nephritis with anti-CD4OL compounds
10/29/2003EP1357115A1 Alkanoic acid derivatives, process for their production and use thereof
10/29/2003EP1356108A2 Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
10/29/2003EP1356058A2 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase
10/29/2003EP1356047A2 Human proteins, polynucleotides encoding them and methods of using the same
10/29/2003EP1356046A2 Cytokine receptor zcytor19
10/29/2003EP1356043A2 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
10/29/2003EP1356042A2 Carbohydrate-associated proteins
10/29/2003EP1355943A2 Neurotransmitter transporters
10/29/2003EP1355936A2 Polymer conjugates of neublastin and methods of using same
10/29/2003EP1355921A2 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
10/29/2003EP1355907A1 Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
10/29/2003EP1355905A1 Pyrazole compounds useful as protein kinase inhibitors
10/29/2003EP1355902A1 Sulfonamide compounds, their preparation and use
10/29/2003EP1355884A1 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
10/29/2003EP1355875A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
10/29/2003EP1355655A2 Compositions and methods for improving kidney function
10/29/2003EP1355649A2 Pharmaceutical formulation containing pyrazolo 4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
10/29/2003EP1355645A2 Method for treating fibrotic diseases or other indications iiic
10/29/2003EP1355642A2 INHIBITION OF NF-(k)B BY TRITERPENE COMPOSITIONS
10/29/2003EP1355641A2 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
10/29/2003EP1355563A2 METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
10/29/2003EP1248530B1 Canine health diet
10/29/2003EP1107940B1 Vitamin d3 mimics
10/29/2003EP0994711B1 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
10/29/2003EP0831822B1 The use of calcium channel antagonists for treating cardiac, renal and gastrointestinal disorders and hypertension
10/29/2003CN1452628A 4-halogenated 17-methylene steroids, method for production thereof and pharmaceutical compositions contg. these compounds
10/29/2003CN1452622A Piperzine devivs.
10/29/2003CN1452613A Amorphous torasemide modification
10/29/2003CN1452492A Neuroprotective peptides
10/29/2003CN1452483A IL-8 receptor antagonists
10/29/2003CN1451418A Chinese medicine and prescription for treatment of hypertrophy of prostate
10/29/2003CN1451409A Novel medicine for treating urinary retention and preparing method thereof
10/29/2003CN1451388A Medicine for preventing and treating infectious diseases caused by virus, e.g. SARS
10/29/2003CA2445913A1 Method of treatment
10/28/2003US6639111 Bind on EP4 subtype receptor selectively and binds on the other subtype receptors weakly; side-effect reduction; autoimmune diseases; asthma; bone disorders; degenerative nerve diseases; sleeping disorders; anticoagulants
10/28/2003US6638942 Spiro-indolines as Y5 receptor antagonists
1 ... 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 ... 562